Melanoma Clinical Trial
Vaccine Therapy in Treating Patients With Stage IV Melanoma
Summary
Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma. Vaccines may make the body build an immune response to kill tumor cells.
Full Description
OBJECTIVES:
I. Determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, and rate of sensitization of T cells at each dose level in patients with melanoma receiving dendritic cell vaccine.
II. Determine the overall (complete and partial) response rate, duration of response, and optimal route of administration in this patient population.
OUTLINE: This is a dose escalation study. Patients are randomized to one of three treatment arms.
All patients undergo leukopheresis to obtain lymphocyte and myeloid origin mononuclear cell fractions for preparation of dendritic cell (DC) vaccine. In each arm, cohorts of up to 5 patients receive escalating doses of vaccine. The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 or more of 5 patients experience dose-limiting toxicity. Randomization ceases if the MTD has been reached in 2 arms, although accrual may continue. Treatment repeats every 2 weeks for a total of 4 doses.
Arm I: Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
Arm II: Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
Arm III: Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
Patients are followed at 2 weeks and then monthly for 3 months.
Eligibility Criteria
DISEASE CHARACTERISTICS:
-Histologically confirmed stage IV melanoma Must be MHC Class I HLA-A2.1
PATIENT CHARACTERISTICS:
Age: Over 18
Performance status: ECOG 0-1
Life expectancy: At least 2 months
Platelet count at least 100,000/mm3
INR no greater than 1.5 mg/dL
No coagulopathies including thrombocytopenia
Partial thromboplastin time no greater than 50 seconds
No major cardiac illness
No major respiratory illness
No active systemic infection or other illness
No peripheral vascular disease
Not pregnant or nursing
Effective contraception required of all fertile patients during and for one month after completion of treatment
PRIOR CONCURRENT THERAPY:
At least 30 days since prior immunotherapy
No concurrent immunotherapy
At least 30 days since prior chemotherapy
No concurrent chemotherapy
At least 30 days since prior radiotherapy
No concurrent radiotherapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19104, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.